Aesthetic Medical International Holdings, a Chinese aesthetic medical services provider, on Tuesday announced terms for its U.S. initial public offering (IPO).

The Shenzhen-based company plans to offer 2.5 million American Depositary Shares (ADSs), each representing three of the company's ordinary shares, at a price range of 11-13 U.S. dollars, said its latest prospectus.

The beauty treatment provider has applied to list the ADSs on the Nasdaq Global Market under the symbol "AIH."

Cantor Fitzgerald, Haitong International and Prime Number Capital are the joint bookrunners on the deal.

The company is the third-largest private aesthetic medical services provider in China in terms of revenue in 2018, which registered 110.9 million dollars, according to U.S. consultancy Frost & Sullivan.

Its revenue grew to 57.3 million dollars in the six months ending June 30, up from around 50.3 dollars in the six months ending June 30, 2018, according to its prospectus.

The firm primarily offers surgical aesthetic treatments, such as eye surgery and breast augmentation, as well as non-surgical aesthetic treatments, such as laser and ultrasound treatments.

The overall aesthetic medical services market in China grew rapidly from 2014 to 2018, and is expected to grow to around 50.85 billion dollars in 2023, representing a CAGR (compound annual growth rate) of 24.2 percent from 2018 to 2023, according to Frost & Sullivan.